These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22360925)

  • 1. Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes.
    McDonald TJ; McEneny J; Pearson ER; Thanabalasingham G; Szopa M; Shields BM; Ellard S; Owen KR; Malecki MT; Hattersley AT; Young IS
    Clin Chim Acta; 2012 May; 413(9-10):927-32. PubMed ID: 22360925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
    Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
    Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
    Fendler W; Borowiec M; Antosik K; Szadkowska A; Deja G; Jarosz-Chobot P; Mysliwiec M; Wyka K; Pietrzak I; Skupien J; Malecki MT; Mlynarski W
    Clin Endocrinol (Oxf); 2011 Sep; 75(3):321-7. PubMed ID: 21521320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
    Mughal SA; Park R; Nowak N; Gloyn AL; Karpe F; Matile H; Malecki MT; McCarthy MI; Stoffel M; Owen KR
    Diabet Med; 2013 Feb; 30(2):246-50. PubMed ID: 23157689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level.
    Fendler W; Rizzo M; Borowiec M; Malachowska B; Antosik K; Szadkowska A; Banach M; Urbanska-Kosinska M; Szopa M; Malecki M; Mlynarski W
    Acta Diabetol; 2014 Aug; 51(4):625-32. PubMed ID: 24549415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New clinical screening strategy to distinguish
    Ma Y; Gong S; Wang X; Cai X; Xiao X; Gu W; Yang J; Zhong L; Xiao J; Li M; Liu W; Zhang S; Zhou X; Li Y; Zhou L; Zhu Y; Luo Y; Ren Q; Huang X; Gao X; Zhang X; Zhang R; Chen L; Wang F; Wang Q; Hu M; Han X; Ji L
    BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32238361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating CD36 is reduced in HNF1A-MODY carriers.
    Bacon S; Kyithar MP; Schmid J; Costa Pozza A; Handberg A; Byrne MM
    PLoS One; 2013; 8(9):e74577. PubMed ID: 24069322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult-Onset Nonautoimmune Diabetes.
    Juszczak A; Pavić T; Vučković F; Bennett AJ; Shah N; Pape Medvidović E; Groves CJ; Šekerija M; Chandler K; Burrows C; Rojnić Putarek N; Vučić Lovrenčić M; Ćuća Knežević J; James TJ; Gloyn AL; Lauc G; McCarthy MI; Owen KR; Gornik O
    Diabetes Care; 2019 Jan; 42(1):17-26. PubMed ID: 30455330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlates of serum lipids and lipoproteins in Congolese patients with arterial hypertension.
    Lepira FB; M'Buyamba-Kabangu JR; Kayembe KP; Nseka MN
    Cardiovasc J S Afr; 2005; 16(5):249-55. PubMed ID: 16307156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
    Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
    Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
    McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
    Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive lipid-lowering strategy in patients with diabetes mellitus.
    Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
    Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maturity onset diabetes of the young due to
    Pavić T; Juszczak A; Pape Medvidović E; Burrows C; Šekerija M; Bennett AJ; Ćuća Knežević J; Gloyn AL; Lauc G; McCarthy MI; Gornik O; Owen KR
    Biochem Med (Zagreb); 2018 Jun; 28(2):020703. PubMed ID: 29666556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
    Thanabalasingham G; Shah N; Vaxillaire M; Hansen T; Tuomi T; Gašperíková D; Szopa M; Tjora E; James TJ; Kokko P; Loiseleur F; Andersson E; Gaget S; Isomaa B; Nowak N; Raeder H; Stanik J; Njolstad PR; Malecki MT; Klimes I; Groop L; Pedersen O; Froguel P; McCarthy MI; Gloyn AL; Owen KR
    Diabetologia; 2011 Nov; 54(11):2801-10. PubMed ID: 21814873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular background and clinical characteristics of HNF1A MODY in a Polish population.
    Skupien J; Gorczynska-Kosiorz S; Klupa T; Cyganek K; Wanic K; Borowiec M; Sieradzki J; Malecki MT
    Diabetes Metab; 2008 Nov; 34(5):524-8. PubMed ID: 18838325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystatin C is not a good candidate biomarker for HNF1A-MODY.
    Nowak N; Szopa M; Thanabalasingham G; McDonald TJ; Colclough K; Skupien J; James TJ; Kiec-Wilk B; Kozek E; Mlynarski W; Hattersley AT; Owen KR; Malecki MT
    Acta Diabetol; 2013 Oct; 50(5):815-20. PubMed ID: 22350134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
    Owen KR; Thanabalasingham G; James TJ; Karpe F; Farmer AJ; McCarthy MI; Gloyn AL
    Diabetes Care; 2010 Sep; 33(9):1919-24. PubMed ID: 20724646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinguishing the lipid profile of GCK-MODY patients and its correlation with hsCRP levels.
    Ping F; Fu J; Xiao X
    Front Endocrinol (Lausanne); 2022; 13():1024431. PubMed ID: 36387841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
    Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
    Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.